Myriad Genetics
MYGNNasdaqOther · In Vitro & In Vivo Diagnostic Substances · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $164.0M |
| Operating income | −$387.2M | −$123.5M | −$257.4M | −$140.6M | −$190.5M | −$133.7M |
| Net income | −$365.9M | −$127.3M | −$263.3M | −$112.0M | −$27.2M | −$115.2M |
| Total assets | $706.6M | $1.03B | $1.15B | $1.20B | $1.32B | $1.40B |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M | $486.4M |
| Equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M | $918.2M |
| EPS (diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-1.55 |
| Shares out. | 91.3M | 89.9M | 81.2M | 80.0M | 80.0M | 74.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −47.0%
- Net margin
- −44.4%
- Return on equity
- −99.4%
- Return on assets
- −51.8%
- Return on capital (ROCE)
- −67.6%
- Liabilities / assets
- 47.9%
- Debt / equity
- 0.92×
- Book value / share
- $4.03
- Revenue growth (YoY)
- −1.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.88distress
- Accruals / assets
- −52.0%clean
- Beneish M-Score
- -5.26normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 2, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- State Street CorpPassive (13G)May 12, 2026
- Blackrock, Inc.Passive (13G)Apr 7, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Feb 11, 2026
- Glenview Capital Management, LlcPassive (13G)Jan 13, 2026
- Barclays PlcPassive (13G)Nov 12, 2025
- Disciplined Growth Investors Inc /MnPassive (13G)Aug 14, 2025
- Wellington Management Group LlpPassive (13G)Aug 12, 2025
- Camber Capital Management LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.3M | 3.8 | +5.7% |
| Apr 30, 2026 | 7.9M | 8.4 | -4.3% |
| Apr 15, 2026 | 8.2M | 7.9 | -6.0% |
| Mar 31, 2026 | 8.8M | 2.9 | -25.1% |
| Mar 13, 2026 | 11.7M | 5.8 | +0.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Results of operationsFeb 23, 2026
- Results of operationsJan 12, 2026
- Results of operationsNov 3, 2025
- Director / officer changeOct 7, 2025
- Director / officer changeOct 3, 2025
- Director / officer changeAug 18, 2025
- Results of operationsAug 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4FORM 4May 14, 2026
- SCHEDULE 13GMay 12, 2026
- 10-QMay 6, 2026
- 8-KMay 5, 2026
- 4FORM 4May 4, 2026
- 4FORM 4Apr 15, 2026
- 4FORM 4Apr 15, 2026
- ARSApr 14, 2026
- DEFA14AApr 14, 2026
- DEF 14AApr 14, 2026
- SCHEDULE 13G/AApr 7, 2026
- SCHEDULE 13G/AMar 27, 2026
- 4FORM 4Mar 23, 2026
- 4FORM 4Mar 23, 2026
- 4FORM 4Mar 23, 2026
Corporate family
Spin-offs from Myriad Genetics (1)
- Myrexis, Inc.completedJun 30, 2009details
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.